Twenty-one of 29 patients suffering from myasthenia gravis derived benefit from a short intensive course of adrenocorticotrophin (ACTH). The mean duration of benefit was approximately six months. The best results were obtained in patients with a short history of myasthenia. Transient deterioration during the course of injections was encountered in some cases but necessitated assisted respiration only in patients with severe generalized weakness before treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC494671 | PMC |
| http://dx.doi.org/10.1136/jnnp.37.4.412 | DOI Listing |
Publication Analysis
Top Keywords
myasthenia gravis
8
benefit adrenocorticotrophin
4
adrenocorticotrophin myasthenia
4
gravis twenty-one
4
twenty-one patients
4
patients suffering
4
suffering myasthenia
4
gravis derived
4
derived benefit
4
benefit short
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!